Clinical Trial

Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy

Study acronym: DL-ESCC
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 28, 2025 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aims to develop and validate a deep learning model to predict pathological complete response (pCR) in patients with esophageal squamous cell carcinoma who have undergone neoadjuvant immunochemotherapy. Clinical, imaging, and pathological data from previously treated patients will be collected and analyzed. The model is expected to assist in predicting treatment outcomes and guide personalized therapeutic strategies.
Trial Details
NCT Number NCT07088354
Lead Sponsor Tongji Hospital
Conditions Esophageal Squamous Cell Carcinoma, Neoadjuvant Immunochemotherapy, Pathological Complete Response, Deep Learning
Enrollment 300 participants
Start Date 2025-03-01
Primary Completion 2026-06-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-28